#USA #New York #Faruqi & Faruqi #PepGen Inc. #SEC Lawsuit

Faruqi & Faruqi Investigates Investor Claims Against PepGen Inc.

Faruqi & Faruqi, LLP, a prominent securities law firm recognized nationally for handling significant securities litigation, recently announced it is looking into potential claims on behalf of investors who may have suffered financial losses related to PepGen Inc. (NASDAQ: PEPG). The firm is particularly urging those who acquired PepGen stock between March 7, 2024, and March 3, 2025, to step forward and discuss their legal options.

In recent months, PepGen Inc. has faced scrutiny and significant challenges regarding its clinical trials, specifically concerning the drug PGN-EDO51, which is intended for treating Duchenne muscular dystrophy (DMD). Allegations against the company assert that PepGen and its executives may have violated federal securities laws by providing false or misleading information about the efficacy and safety of PGN-EDO51. This includes claims that the CONNECT2 clinical study was not only deficient but that its risks were downplayed to investors.

The investigation follows a series of troubling announcements from PepGen regarding its clinical trials. On July 30, 2024, the company announced what it labeled as "positive clinical data" from its ongoing CONNECT1 study. However, analysts were quick to point out that the results fell below expectations, raising questions about PepGen's earlier amplification of its drug's potential. Following this news, PepGen’s stock experienced a drastic decline, falling over 32%. This was just the beginning of a trend, as subsequent releases regarding clinical holds from the FDA and halted trials contributed to further downturns in stock prices.

By December 16, 2024, PepGen revealed that it received a clinical hold notice from the FDA on its IND application, referencing potential safety concerns tied to the CONNECT2 study. The revelation resulted in a significant drop in share value again. As the firm continued to disclose safety concerns throughout 2025, including those relating to patient health in trials, investors saw their confidence falter, driving stock prices down by nearly 22% after updates on January 29, 2025.

The last straw came in May 2025 when PepGen announced it would discontinue its DMD programs after PGN-EDO51 failed to meet target dystrophin levels measured in clinical trials.

Faruqi & Faruqi's investigation highlights the urgency for those affected by these disclosures. Investors interested in stepping forward are reminded that the deadline to seek participation as lead plaintiffs in this federal securities class action is August 11, 2025. The role of the lead plaintiff is crucial, as this individual will guide and direct the litigation on behalf of all affected investors. Each investor's participation remains unaffected by the choice to step into this role or to remain an undisclosed member of the class.

The firm calls upon anyone with insight regarding PepGen's conduct, including former employees or whistleblowers, to reach out via established communication channels. The legal firm aims to ensure that justice is served for investors who may have lost money reliant on PepGen's public statements and assurances.

For additional details regarding this unfolding case and how to participate, investors can visit the firm’s dedicated webpage at Faruqi & Faruqi Class Actions or contact partner Josh Wilson directly. With the ramifications of these investigations potentially impacting many stakeholders, it is crucial for investors to stay informed and involved. Updates can also be found across Faruqi & Faruqi's social media platforms.

As the landscape evolves, maintaining transparency and accountability in the pharmaceutical sector is critical, and shareholder activism plays a significant role in protecting investor interests.